Frontiers in Immunology

OCT 23, 2026 · JOURNAL ARTICLE

Advances in photothermal-driven tumor immunomodulation and synergistic therapy

Frontiers in Immunology

Photothermal therapy (PTT) is a local treatment that uses photothermal conversion agents (PTAs) to absorb light and produce heat in tumor tissue. The direct result is tumor ablatio

OCT 23, 2026 · JOURNAL ARTICLE

Persistent nodal disease with squamous differentiation and spatial immune heterogeneity after chemoimmunotherapy in biliary tract cancer: a high-resolution pathological analysis

Frontiers in Immunology

Background Heterogeneous responses across disease sites may occur after systemic therapy for biliary tract cancer (BTC), but their pathological and immune features remain poorly ch

OCT 22, 2026 · JOURNAL ARTICLE

Astragaloside IV and tumor microenvironmental barriers: immune mechanisms, evidence hierarchy, and implications for checkpoint blockade

Frontiers in Immunology

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy; however, primary and acquired resistance remain prevalent in solid tumors. Challenges such as poor T-cell in

OCT 22, 2026 · JOURNAL ARTICLE

Short-chain fatty acids and intestinal macrophage immunometabolism in metabolic syndrome: mechanisms and implications for chronic low-grade inflammation

Frontiers in Immunology

Chronic low-grade inflammation (CLGI) is a major feature of metabolic syndrome (MetS), and the intestinal mucosa is an important site where microbial metabolites interact with host

OCT 22, 2026 · JOURNAL ARTICLE

Therapy-induced methionine competition in bladder cancer: MAT2A-SAM axis remodeling as a metabolic immune checkpoint

Frontiers in Immunology

Bladder cancer is increasingly treated with platinum chemotherapy, immune checkpoint blockade, and antibody-drug conjugates, but treatment resistance remains common. Methionine con

OCT 22, 2026 · JOURNAL ARTICLE

Defining safe bladder preservation in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: beyond complete response

Frontiers in Immunology

Bacillus Calmette-Guerin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC) remains a challenging disease state in which radical cystectomy (RC) provides the m

OCT 22, 2026 · REVIEW

Hormonal and nutritional biomarkers in immune checkpoint inhibition for gastrointestinal cancers: a narrative review

Frontiers in Immunology

Immune checkpoint inhibitors (ICIs) have improved treatment outcomes in selected gastrointestinal cancers, although the efficacy and frequency of immune-related adverse events (irA

OCT 22, 2026 · JOURNAL ARTICLE

Long non-coding RNA-mediated stress adaptation and immune remodeling in non-small cell lung cancer: molecular mechanisms and therapeutic implications

Frontiers in Immunology

Non-small cell lung cancer (NSCLC) remains the predominant subtype of lung cancer and a leading cause of cancer-related mortality worldwide. Therapeutic failure is largely driven b